Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: Evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 541-551

  Pritchard, Kathleen I ^a   Munro, Alison ^b   O'Malley, Frances P ^a,c   Tu, Dongsheng ^d   Li, Xiao ^d   Levine, Mark N ^e   Shepherd, Lois ^d   Chia, Stephen ^f,g   Bartlett, John M S ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Anthracycline; Centromere; CEP17; Chromosome; Duplication

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CENTROMERE; CHROMOSOME 17; CHROMOSOME DUPLICATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SURVIVAL;

ADULT; ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CENTROMERE; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE DUPLICATION; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856224113     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1840-4     Document Type: Article

References (27)

1. A Di Leo D Gancberg D Larsimont, et al. 2002 HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 1107 1116 12006526 1:CAS:528:DC%2BD38XksVSqu7s%3D (Pubitemid 34517647)
2. A Di Leo D Larsimont M Beauduim 2001 Her-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12 1081 1089 11583189 10.1023/A:1011669223035 1:STN:280:DC%2BD3MrjsFehsg%3D%3D (Pubitemid 32834488)
3. KI Pritchard LE Shepherd FA O'Malley, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 16707747 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D (Pubitemid 43736610)
4. HB Muss AD Thor DA Berry, et al. 1994 C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer New Engl J Med 330 1260 1266 7908410 10.1056/NEJM199405053301802 1:STN:280: DyaK2c7psFensQ%3D%3D (Pubitemid 24129958)
5. S Paik J Bryant E Tan-Chiu, et al. 2000 HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National surgical adjuvant breast and bowel project protocol B-15 J Natl Cancer Inst 92 1991 1998 11121461 10.1093/jnci/92.24.1991 1:CAS:528:DC%2BD3MXkvF2rsw%3D%3D (Pubitemid 32045895)
6. S Paik J Bryant C Park, et al. 1998 ErbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer J Natl Cancer Inst 90 1361 1370 9747867 10.1093/jnci/90.18.1361 1:CAS:528:DyaK1cXmtlelurw%3D (Pubitemid 28439960)
7. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20 (Pubitemid 351767337)
8. B Dhesy-Thind KI Pritchard H Messersmith, et al. 2008 Her-2/neu in systemic therapy for women with breast cancer: a systemic review Breast Cancer Res Treat 109 209 229 17636396 10.1007/s10549-007-9656-y 1:CAS:528: DC%2BD1cXlsV2ntrs%3D (Pubitemid 351644854)
9. M De Laurentiis G Arpino E Massarelli, et al. 2005 A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer Clin Cancer Res 11 4741 4748 16000569 10.1158/1078-0432.CCR-04-2569 (Pubitemid 41557193)
10. DJ Slamon J Mackey J Crown, et al. 2007 Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease [abstract] Breast Cancer Res Treat 106 112 (Abstract 13)
11. AS Knoop H Knudsen E Balslev, et al. 2005 Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group J Clin Oncol 23 7483 7490 16234514 10.1200/JCO.2005.11. 007 1:CAS:528:DC%2BD2MXht1WrsrzK (Pubitemid 46291811)
12. F O'Malley S Chia D Tu, et al. 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 644 650 19401546 10.1093/jnci/djp067
13. KI Pritchard H Messersmith L Elavathil, et al. 2008 Her-2 and topoisomerase II as predictors of response to chemotherapy J Clin Oncol 26 1 9 10.1200/JCO.2007.14.5920
14. JMS Bartlett A Munro DA Cameron, et al. 2008 Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial J Clin Oncol 26 5027 5035 18768436 10.1200/JCO.2007.14.6597 1:CAS:528:DC%2BD1cXhsVGhsrrE
15. JMS Bartlett A Munro JA Dunn, et al. 2010 Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) Lancet Oncol 11 266 274 20079691 10.1016/S1470-2045(10)70006-1 1:CAS:528:DC%2BC3cXisFGrtr8%3D
16. A Di Leo C Desmedt JMS Bartlett, et al. 2010 Final results of a meta analysis testing HER2 and topoisomerase II genes as predictors of incremental benefit from anthracyclines in breast cancer [abstract] J Clin Oncol 28 72S
17. A Di Leo J Isola F Piette, et al. 2008 A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy [abstract] Breast Cancer Res Treat 107 24s (Abstract 705)
18. TA Jarvinen M Tanner V Rantanen, et al. 2000 Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer Am J Pathol 156 839 847 10702400 10.1016/S0002-9440(10)64952-8 1:CAS:528: DC%2BD3cXitVerurc%3D (Pubitemid 30626942)
19. FA O'Malley S Chia D Tu, et al. 2011 Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial Breast Cancer Res Treat 128 1511 1515
20. TA Jarvinen J Kononen M Peltohuikko J Isola 1996 Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer Am J Pathol 148 2073 2082 8669491 1:STN:280:DyaK283jsVaruw%3D%3D (Pubitemid 26170530)
21. JMS Bartlett IO Ellis M Dowsett, et al. 2007 Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor negative, but with grade in those with ER positive early stage breast cancer suitable for cytotoxic chemotherapy J Clin Oncol 25 4423 4430 17906205 10.1200/JCO.2007.11.0973 (Pubitemid 350013848)
22. MN Levine VH Bramwell KI Pritchard, et al. 1998 A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methrotrexate, fluorouracil in premenopausal women with node positive breast cancer J Clin Oncol 16 2651 2658 9704715 1:CAS:528: DyaK1cXlsFCguro%3D (Pubitemid 28363028)
23. MN Levine KI Pritchard VH Bramwell, et al. 2005 A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5 J Clin Oncol 23 5166 5170 16051958 10.1200/JCO.2005.09. 423 1:CAS:528:DC%2BD2MXpsFWmtb8%3D (Pubitemid 46224025)
24. CW Elston 1991 Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991. tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
25. MM Reinholz RB Jenkins DW Hillman, et al. 2007 The clinical significance of poly 17 in the HER2 and N98431 intergroup adjuvant trastuzumab trial [abstract] Breast Cancer Res Treat 107 S11 (Abstract 36)
26. I-T Yeh MA Martin RS Robetorye, et al. 2009 Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event Mod Pathol 22 1169 1175 19448591 10.1038/modpathol.2009.78 1:CAS:528:DC%2BD1MXhtVKgsbfK
27. C Marchio MB Lambros P Gugliotta, et al. 2009 Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis J Pathol 219 16 24 19670217 10.1002/path.2574 1:CAS:528:DC%2BD1MXhtFGgs7%2FI